A randomized phase 1b/2 trial of ABBV‐916 in adults with early Alzheimer's disease
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71715 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Shau Yu Lynch und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Development, AbbVie Inc., North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc., AbbVie.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION ABBV‐916, an anti‐amyloid immunotherapy, was evaluated in patients with early Alzheimer's disease (AD). METHODS This phase 1b/2, double‐blind, placebo‐controlled study consisted of two stages: multiple ascending dose (Stage A) and dose expansion (Stage B). In Stage A, patients were randomized to one of six planned cohorts to receive intravenous ABBV‐916 (10 mg to 3000 mg) or placebo monthly through week 24. Assessments included amyloid PET, blood‐based biomarkers, pharmacokinetics (PK), and safety. Dose selection for Stage B was to be based on results from Stage A. RESULTS One hundred six patients were randomized to ABBV‐916 or placebo. The 3000 mg dose was reduced to 2000 mg and subsequently to 900 mg after safety review. Dose‐proportional PK were observed, and amyloid reduction was observed over 24 weeks at doses ≥300 mg. Most adverse events were non‐serious amyloid‐related imaging abnormalities. The program ended before dose expansion due to business considerations. DISCUSSION Amyloid clearance rate and safety of ABBV‐916 were generally comparable to approved anti‐amyloid AD therapies. CLINICAL TRIAL REGISTRATION INFORMATION NCT05291234
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Development, AbbVie Inc., North Chicago, Illinois, USA.
- Statistics, AbbVie Inc., North Chicago, Illinois, USA.
- Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.
- Global Patient Safety, AbbVie Inc., North Chicago, Illinois, USA.
- Discovery Science, AbbVie Inc., North Chicago, Illinois, USA.
- Precision Medicine, AbbVie Inc., North Chicago, Illinois, USA.
ORCID-Profile: Shau Yu Lynch
Förderung
- AbbVie Inc.
- AbbVie
Zitieren
APA
Lynch, S. Y., Wang, Y., Wang, D., Bachhav, S. S., Xiong, H., Boiser, J., Stage, E., Bannon, A. W., Graff, O., & Florian, H. (2026). A randomized phase 1b/2 trial of ABBV‐916 in adults with early Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71715
Vancouver
Lynch SY, Wang Y, Wang D, Bachhav SS, Xiong H, Boiser J, et al. A randomized phase 1b/2 trial of ABBV‐916 in adults with early Alzheimer's disease. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71715
BibTeX
@article{Lynch2026,
author = {Lynch, Shau Yu and Wang, Yamin and Wang, Deli and Bachhav, Sagar S and Xiong, Hao and Boiser, Joey and Stage, Edwin and Bannon, Anthony W and Graff, Ole and Florian, Hana},
title = {A randomized phase 1b/2 trial of ABBV‐916 in adults with early Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71715}
}
EUVIMED